Durvalumab plus tremelimumab for advanced hepatocellular carcinoma is associated with a neutrophil/lymphocyte ratio

被引：0
|
作者：
Sugimoto, Rie [1 ]
Senjyuu, Takeshi [2 ]
Aratake, Yoshifusa [3 ]
Kuwano, Akifumi [4 ]
Ueda, Akihiro [5 ]
Nakamura, Tsukasa [6 ]
Goya, Takeshi [7 ]
Morita, Yuusuke [1 ]
Tanaka, Yuki [1 ]
Kojima, Motoyuki [3 ]
Tanaka, Masatake [7 ]
机构：
[1] NHO Kyushu Canc Ctr, Dept Hepatobiliary Pancreatol, Fukuoka, Japan
[2] Kyushu Rosai Hosp, Kitakyushu, Fukuoka, Japan
[3] NHO Kyusyu Med Ctr, Fukuoka, Japan
[4] Iizuka Hosp, Iizuka, Fukuoka, Japan
[5] Saiseikai Fukuoka Gen Hosp, Fukuoka, Japan
[6] Fukuoka City Hosp, Fukuoka, Japan
[7] Kyushu Univ, Dept Med & Bioregulatory Sience, Fukuoka, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2184
引用
收藏
页码：963 / 963
页数：1
相关论文
共 50 条
  • [41] Complete response to tremelimumab plus durvalumab treatment in hepatocellular carcinoma with a bile duct tumor thrombus: A case report
    Ishihara, Nobuaki
    Komatsu, Shohei
    Kido, Masahiro
    Gon, Hidetoshi
    Fukushima, Kenji
    Urade, Takeshi
    Yoshida, Toshihiko
    Arai, Keisuke
    Yanagimoto, Hiroaki
    Toyama, Hirochika
    Fukumoto, Takumi
    ONCOLOGY LETTERS, 2024, 28 (01)
  • [42] Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
    Mori, Nami
    Tamaki, Nobuharu
    Takaki, Shintaro
    Tsuji, Keiji
    Tada, Toshifumi
    Nakamura, Shinichiro
    Ochi, Hironori
    Mashiba, Toshie
    Doisaki, Masao
    Marusawa, Hiroyuki
    Kobashi, Haruhiko
    Fujii, Hideki
    Ogawa, Chikara
    Nonogi, Michiko
    Arai, Hirotaka
    Uchida, Yasushi
    Urawa, Naohito
    Narita, Ryoichi
    Akahane, Takehiro
    Kondo, Masahiko
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Izumi, Namiki
    Kurosaki, Masayuki
    INVESTIGATIONAL NEW DRUGS, 2024, : 559 - 565
  • [43] Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib
    Hong, Young Mi
    Yoon, Ki Tae
    Hwang, Tae Ho
    Heo, Jeong
    Woo, Hyun Young
    Cho, Mong
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (10) : 1250 - 1255
  • [44] The Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib
    Zheng, You-Bing
    Zhao, Wei
    Liu, Bing
    Lu, Li-Gong
    He, Xu
    Huang, Jian-Wen
    Li, Yong
    Hu, Bao-Shan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (09) : 5527 - 5531
  • [45] Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
    Nicole L. France
    Hannah A. Blair
    Targeted Oncology, 2024, 19 : 115 - 123
  • [46] Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
    France, Nicole L.
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2024, 19 (01) : 115 - 123
  • [47] NEUTROPHIL LYMPHOCYTE RATIO AND PLATELET LYMPHOCYTE RATIO ARE EXCELLENT MARKERS FOR PREDICTING SURVIVAL AND SEVERITY OF HEPATOCELLULAR CARCINOMA
    Walinjkar, Sagar
    Arora, Anil
    Kumar, Ashish
    Sharma, Praveen
    Bansal, Naresh
    GUT, 2020, 69 : A90 - A91
  • [48] Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy
    Dharmapuri, Sirish
    Ozbek, Umut
    Lin, Jung-Yi
    Sung, Max
    Schwartz, Myron
    Branch, Andrea D.
    Ang, Celina
    CANCER MEDICINE, 2020, 9 (14): : 4962 - 4970
  • [49] Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival
    Peng, Wei
    Li, Chuan
    Wen, Tian-Fu
    Yan, Lv-Nan
    Li, Bo
    Wang, Wen-Tao
    Yang, Jia-Yin
    Xu, Ming-Qing
    JOURNAL OF SURGICAL RESEARCH, 2014, 192 (02) : 402 - 408
  • [50] Neutrophil-lymphocyte ratio is useful for the prognosis of patients with hepatocellular carcinoma
    Kayadibi, Huseyin
    Sertoglu, Erdim
    Uyanik, Metin
    Tapan, Serkan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (28) : 9631 - 9632
12345